Print Page RSS Feeds Email Alerts

Release Details

Idera Pharmaceuticals to Present Positive Phase 1 Trial Results on TLR Antagonist IMO-8400 for the Treatment of Autoimmune Diseases at FOCIS 2013

Jun 21, 2013
PDF Version

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 21, 2013-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will present positive Phase 1 trial results on IMO-8400, a selective inhibitor of Toll-like receptors (TLRs) 7, 8 and 9 and a lead candidate for the treatment of autoimmune diseases, at the 13th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS), June 27-30, 2013, in Boston, MA.

Details of the presentation are as follows:

     

Date:

Saturday, June 29, 2013

Time:

6:30-7:45pm ET

Location:

Commonwealth Hall, The Boston Seaport Hotel

Abstract Number:

S.85

Title:

Phase 1 clinical trial of IMO-8400, an antagonist of Toll-like receptors 7, 8 and 9
 

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals applies its proprietary Toll-like receptor (TLR) drug discovery platform to create immunomodulatory drug candidates and has a clinical development program in autoimmune diseases. Additionally, Idera has a collaboration with Merck & Co. for the use of TLR-targeted candidates as vaccine adjuvants for cancer, infectious diseases and Alzheimer’s disease. For more information, visit http://www.iderapharma.com.

Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
larcudi@iderapharma.com